Delivery of cisplatin from Pluronic co-polymer systems: liposome inclusion and alginate coupling.

J Biomater Sci Polym Ed

Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, 259 Wen-Hwa 1st Road, Kweishan, Taoyuan, Taiwan.

Published: July 2009

The aim of this work was to evaluate the use of Pluronic F127 (PF) hydrogels incorporating liposomes and/or grafted with alginate (AP) for the parenteral delivery of cisplatin. The physicochemical properties such as scanning electron microscopy (SEM), polarity and sol-gel transition temperature, as well as in vitro drug release of developed hydrogels were examined. The sol-gel temperature of PF, PF with liposomes and AP was 26.4, 19.7 and 26.6 degrees C, respectively. A hydrogel with stronger strength was obtained by alginate coupling (AP) according to SEM images and viscosity kinetics as compared to PF. Both liposomes and hydrogels could sustain the release of cisplatin to a certain level. The drug release from the vehicles decreased in the order of PF > liposomes > or = AP > or = PF/liposomes > AP/liposomes. The burst release effect of cisplatin was inhibited when using the AP/liposomes composite system as the vehicle. Formulations were administered intratumorally in melanoma-bearing mice. The respective liposomes or hydrogels did not increase cisplatin accumulation in melanomas compared to the control (aqueous solution). PF/liposomes and AP/liposomes, respectively, increased cisplatin deposition by 2.5- and 4.4-fold. To our best of knowledge, the present work is the first report to investigate the drug delivery from PF-alginate conjugates.

Download full-text PDF

Source
http://dx.doi.org/10.1163/156856209X444493DOI Listing

Publication Analysis

Top Keywords

delivery cisplatin
8
alginate coupling
8
drug release
8
liposomes hydrogels
8
release cisplatin
8
pf/liposomes ap/liposomes
8
liposomes
5
cisplatin
5
cisplatin pluronic
4
pluronic co-polymer
4

Similar Publications

Hyaluronic acid modified metal-organic frameworks loading cisplatin achieve combined chemodynamic therapy and chemotherapy for lung cancer.

Int J Biol Macromol

January 2025

Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, PR China; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan 646000, PR China. Electronic address:

As one of the most commonly used chemotherapeutic agents in clinical practice, cisplatin is unable to selectively accumulate in tumor tissue due to its lack of targeting ability, leading to increased systemic toxicities. Additionally, the effectiveness of monotherapy is greatly limited. Therefore, the development of new cisplatin-based drug delivery systems is essential to improve the effectiveness of tumor treatment.

View Article and Find Full Text PDF

This study explores the development of a sustainable drug delivery system using cellulose nanoparticles (CNPs) derived from potato pulp for the controlled release of phosphoaminopyrazine (PAP), a promising anticancer agent. CNPs were synthesized via nanoprecipitation, and PAP was loaded through in-situ nanoprecipitation, achieving a high loading efficiency of 79.2 %.

View Article and Find Full Text PDF

Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models.

Front Oncol

January 2025

Departamento de Radiologia e Oncologia, Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, Brazil.

Introduction: Intraperitoneal chemotherapy for ovarian cancer treatment has controversial benefits as most methodologies are associated with significant morbidity. We carried out a systematic review to compare tumor response, measured by tumor weight and volume, between intraperitoneal chemotherapy delivered via drug delivery systems (DDSs) and free intraperitoneal chemotherapy in animal models of ovarian cancer. The secondary aim was to assess the toxicity of DDS-delivered chemotherapy, based on changes in animal body weight.

View Article and Find Full Text PDF

Ovarian cancer is a leading cause of cancer-related deaths in women, and the development of chemoresistance remains a major challenge during and after its treatment. Exosomes, small extracellular vesicles involved in intercellular communication, have emerged as potential biomarkers and therapeutic targets in ovarian cancer. This review summarizes the current literature on differences in exosomal protein/gene expression between chemosensitive and chemoresistant ovarian cancer, and the effects of exosomal modifications on chemotherapeutic response.

View Article and Find Full Text PDF

Nanocarrier-mediated cancer therapy with cisplatin: .

Heliyon

April 2024

Institute for Health and Sport, College of Health and Medicine, Victoria University, Melbourne, Victoria, Australia.

Aims: Cisplatin is a frontline chemotherapeutic utilized to attenuate multiple cancers in the clinic. Given its side-effects, a new cisplatin formulation which could prevent cytotoxicity, metabolic deficiencies and metastasis is much needed. This study investigates whether nanocarriers can provide a better mode of drug delivery in preclinical cancer models seeking a potent anticancer therapeutic agent.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!